EXOME

all the information, none of the junk | biotech • healthcare • life sciences

BIND Names Former Bristol Oncology Exec New CSO

Xconomy Boston — 

Cambridge, MA-based Bind Therapeutics (NASDAQ: BIND) named Jonathan Yingling its new chief scientific officer. Yingling had been overseeing Bristol-Myers Squibb’s oncology research portfolio, and spent 13 years at Eli Lilly before that.